Benzinga | Jan 12, 2022 09:44AM EST

BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $153

BMO Capital analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $134 to $153.